Midazolam in patients receiving anticancer chemotherapy and antiemetics

Lisa M. Potanovich, Katherine M W Pisters, Mark G. Kris, Leslie B. Tyson, Rebecca A. Clark, Lorraine Baltzer, Richard J. Gralla

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Benzodiazepines lessen anxiety and improve comfort in cancer patients. Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations. Two consecutive trials were undertaken to study midazolam as an adjunct in patients receiving anticancer chemotherapy. Each studied midazolam given as a short infusion 30 min prior to chemotherapy at dose levels ranging from 0.01 to 0.05 mg/kg. Trial I determined the safety, sedation, and dose of midazolam in patients receiving chemotherapy of low to moderate emetic potential. Twenty-two patients were entered. No significant respiratory depression or oxygen desaturation was observed. At the optimal dose level (0.04 mg/kg), sedation began a median of 3 min following administration and continued for a median of 38 min. Sixty-four percent of patients experienced mild sedation. Trial II studied the same doses of midazolam when used in combination with intravenous metoclopramide and dexamethasone in patients receiving cisplatin≥100 mg/m2. Nineteen patients were entered; 79% experienced mild sedation. At the 0.04-mg/kg dose level, sedation began a median of 18 min following administration and continued for a median of 170 min. Midazolam can be given safely to patients receiving chemotherapy with and without concomitant antiemetics. The predictability and duration of its sedative effects suggest it can be used in outpatients.

Original languageEnglish (US)
Pages (from-to)519-524
Number of pages6
JournalJournal of Pain and Symptom Management
Volume8
Issue number8
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Antiemetics
Midazolam
Drug Therapy
Benzodiazepines
Outpatients
Emetics
Metoclopramide
Hypnotics and Sedatives
Respiratory Insufficiency
Dexamethasone
Anxiety
Oxygen
Safety

Keywords

  • antiemetic
  • anxiety
  • emesis
  • Midazolam
  • nausea
  • supportive care

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Potanovich, L. M., Pisters, K. M. W., Kris, M. G., Tyson, L. B., Clark, R. A., Baltzer, L., & Gralla, R. J. (1993). Midazolam in patients receiving anticancer chemotherapy and antiemetics. Journal of Pain and Symptom Management, 8(8), 519-524. https://doi.org/10.1016/0885-3924(93)90080-F

Midazolam in patients receiving anticancer chemotherapy and antiemetics. / Potanovich, Lisa M.; Pisters, Katherine M W; Kris, Mark G.; Tyson, Leslie B.; Clark, Rebecca A.; Baltzer, Lorraine; Gralla, Richard J.

In: Journal of Pain and Symptom Management, Vol. 8, No. 8, 1993, p. 519-524.

Research output: Contribution to journalArticle

Potanovich, LM, Pisters, KMW, Kris, MG, Tyson, LB, Clark, RA, Baltzer, L & Gralla, RJ 1993, 'Midazolam in patients receiving anticancer chemotherapy and antiemetics', Journal of Pain and Symptom Management, vol. 8, no. 8, pp. 519-524. https://doi.org/10.1016/0885-3924(93)90080-F
Potanovich, Lisa M. ; Pisters, Katherine M W ; Kris, Mark G. ; Tyson, Leslie B. ; Clark, Rebecca A. ; Baltzer, Lorraine ; Gralla, Richard J. / Midazolam in patients receiving anticancer chemotherapy and antiemetics. In: Journal of Pain and Symptom Management. 1993 ; Vol. 8, No. 8. pp. 519-524.
@article{217a4b282413452885d662aa2126a23b,
title = "Midazolam in patients receiving anticancer chemotherapy and antiemetics",
abstract = "Benzodiazepines lessen anxiety and improve comfort in cancer patients. Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations. Two consecutive trials were undertaken to study midazolam as an adjunct in patients receiving anticancer chemotherapy. Each studied midazolam given as a short infusion 30 min prior to chemotherapy at dose levels ranging from 0.01 to 0.05 mg/kg. Trial I determined the safety, sedation, and dose of midazolam in patients receiving chemotherapy of low to moderate emetic potential. Twenty-two patients were entered. No significant respiratory depression or oxygen desaturation was observed. At the optimal dose level (0.04 mg/kg), sedation began a median of 3 min following administration and continued for a median of 38 min. Sixty-four percent of patients experienced mild sedation. Trial II studied the same doses of midazolam when used in combination with intravenous metoclopramide and dexamethasone in patients receiving cisplatin≥100 mg/m2. Nineteen patients were entered; 79{\%} experienced mild sedation. At the 0.04-mg/kg dose level, sedation began a median of 18 min following administration and continued for a median of 170 min. Midazolam can be given safely to patients receiving chemotherapy with and without concomitant antiemetics. The predictability and duration of its sedative effects suggest it can be used in outpatients.",
keywords = "antiemetic, anxiety, emesis, Midazolam, nausea, supportive care",
author = "Potanovich, {Lisa M.} and Pisters, {Katherine M W} and Kris, {Mark G.} and Tyson, {Leslie B.} and Clark, {Rebecca A.} and Lorraine Baltzer and Gralla, {Richard J.}",
year = "1993",
doi = "10.1016/0885-3924(93)90080-F",
language = "English (US)",
volume = "8",
pages = "519--524",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Midazolam in patients receiving anticancer chemotherapy and antiemetics

AU - Potanovich, Lisa M.

AU - Pisters, Katherine M W

AU - Kris, Mark G.

AU - Tyson, Leslie B.

AU - Clark, Rebecca A.

AU - Baltzer, Lorraine

AU - Gralla, Richard J.

PY - 1993

Y1 - 1993

N2 - Benzodiazepines lessen anxiety and improve comfort in cancer patients. Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations. Two consecutive trials were undertaken to study midazolam as an adjunct in patients receiving anticancer chemotherapy. Each studied midazolam given as a short infusion 30 min prior to chemotherapy at dose levels ranging from 0.01 to 0.05 mg/kg. Trial I determined the safety, sedation, and dose of midazolam in patients receiving chemotherapy of low to moderate emetic potential. Twenty-two patients were entered. No significant respiratory depression or oxygen desaturation was observed. At the optimal dose level (0.04 mg/kg), sedation began a median of 3 min following administration and continued for a median of 38 min. Sixty-four percent of patients experienced mild sedation. Trial II studied the same doses of midazolam when used in combination with intravenous metoclopramide and dexamethasone in patients receiving cisplatin≥100 mg/m2. Nineteen patients were entered; 79% experienced mild sedation. At the 0.04-mg/kg dose level, sedation began a median of 18 min following administration and continued for a median of 170 min. Midazolam can be given safely to patients receiving chemotherapy with and without concomitant antiemetics. The predictability and duration of its sedative effects suggest it can be used in outpatients.

AB - Benzodiazepines lessen anxiety and improve comfort in cancer patients. Midazolam is an effective benzodiazepine with a rapid onset and short duration of action, properties that could permit its use in outpatient areas or in short but stressful situations. Two consecutive trials were undertaken to study midazolam as an adjunct in patients receiving anticancer chemotherapy. Each studied midazolam given as a short infusion 30 min prior to chemotherapy at dose levels ranging from 0.01 to 0.05 mg/kg. Trial I determined the safety, sedation, and dose of midazolam in patients receiving chemotherapy of low to moderate emetic potential. Twenty-two patients were entered. No significant respiratory depression or oxygen desaturation was observed. At the optimal dose level (0.04 mg/kg), sedation began a median of 3 min following administration and continued for a median of 38 min. Sixty-four percent of patients experienced mild sedation. Trial II studied the same doses of midazolam when used in combination with intravenous metoclopramide and dexamethasone in patients receiving cisplatin≥100 mg/m2. Nineteen patients were entered; 79% experienced mild sedation. At the 0.04-mg/kg dose level, sedation began a median of 18 min following administration and continued for a median of 170 min. Midazolam can be given safely to patients receiving chemotherapy with and without concomitant antiemetics. The predictability and duration of its sedative effects suggest it can be used in outpatients.

KW - antiemetic

KW - anxiety

KW - emesis

KW - Midazolam

KW - nausea

KW - supportive care

UR - http://www.scopus.com/inward/record.url?scp=0027133129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027133129&partnerID=8YFLogxK

U2 - 10.1016/0885-3924(93)90080-F

DO - 10.1016/0885-3924(93)90080-F

M3 - Article

VL - 8

SP - 519

EP - 524

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 8

ER -